Medizin
Refine
Year of publication
- 2018 (472) (remove)
Document Type
- Article (439)
- Contribution to a Periodical (9)
- Doctoral Thesis (9)
- Part of Periodical (9)
- Book (3)
- Conference Proceeding (1)
- Preprint (1)
- Report (1)
Has Fulltext
- yes (472)
Is part of the Bibliography
- no (472)
Keywords
- breast cancer (15)
- Mammakarzinom (10)
- Behandlung (8)
- inflammation (7)
- CDK4/6 (6)
- Metastasen (6)
- Neuroscience (6)
- PD1/PDL1 (6)
- Studien (6)
- treatment (6)
- Blood (5)
- Research article (5)
- cancer (5)
- metastases (5)
- Biomarker (4)
- Cirrhosis (4)
- Depression (4)
- Germany (4)
- Hemorrhage (4)
- Inflammation (4)
- Prävention (4)
- Risiko (4)
- Schizophrenia (4)
- diagnosis (4)
- mutual information (4)
- pain (4)
- prevention (4)
- reactive oxygen species (4)
- risk (4)
- trials (4)
- Biomarkers (3)
- Breast cancer (3)
- Cancer (3)
- Cell staining (3)
- EEG microstates (3)
- Flow cytometry (3)
- HIV (3)
- Hepatocellular carcinoma (3)
- Liver diseases (3)
- Mental health and psychiatry (3)
- Morbidity (3)
- Neonates (3)
- Obesity (3)
- Prognosis (3)
- Stem cells (3)
- aging (3)
- autophagy (3)
- chemotherapy (3)
- entropy (3)
- glioblastoma (3)
- information theory (3)
- macrophage (3)
- metastasis (3)
- mitochondria (3)
- regeneration (3)
- sphingolipids (3)
- Alcohol consumption (2)
- Antiretroviral therapy (2)
- Atherosclerosis (2)
- Atrial fibrillation (2)
- Autism (2)
- Autism spectrum disorder (2)
- Autophagy (2)
- BRAF (2)
- Blood pressure (2)
- Brain metastasis (2)
- Brustkrebs (2)
- COPD (2)
- CTGF (2)
- Cardiac magnetic resonance (2)
- Cardiovascular diseases (2)
- Cardiovascular magnetic resonance (2)
- Cell therapy (2)
- Citation analysis (2)
- Complications (2)
- Consensus (2)
- Crystal structure (2)
- Cytoskeleton (2)
- DAA (2)
- Death rates (2)
- Deutschland (2)
- Diabetes (2)
- Diagnose (2)
- Diagnostic markers (2)
- Diagnostic medicine (2)
- Diagnostik (2)
- Emotions (2)
- Etiology (2)
- Evaluation (2)
- Everolimus (2)
- Exercise (2)
- Eyes (2)
- Face (2)
- Fistula (2)
- Früherkennung (2)
- Galaktografie (2)
- Galaktomosynthese (2)
- General practice (2)
- Genome-wide association studies (2)
- Guidelines (2)
- HCC (2)
- Hematology (2)
- Immunology (2)
- Kidney transplantation (2)
- Knees (2)
- Liver fibrosis (2)
- Lokalrezidiv (2)
- Long non-coding RNAs (2)
- MRI (2)
- MRT (2)
- Mamma (2)
- Markovianity (2)
- Medical education (2)
- MicroRNAs (2)
- Mixed methods (2)
- Morphometry (2)
- Mortality (2)
- Multimorbidity (2)
- Multiple chronic conditions (2)
- Musculoskeletal system (2)
- Nachsorge (2)
- Nerve fibers (2)
- Next-generation sequencing (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Operation/Chirurgie (2)
- PCR (2)
- PD1/ PDL1 (2)
- Palliative care [MeSH] (2)
- Patients (2)
- Percutaneous coronary intervention (2)
- Periodontitis (2)
- Polypharmacy (2)
- Primary care (2)
- Prognosefaktoren (2)
- Prostate cancer (2)
- Prädiktivfaktoren (2)
- Pulmonary hypertension (2)
- Reaction time (2)
- Richtlinie (2)
- Scientists (2)
- Sepsis (2)
- Stroke (2)
- Surgical and invasive medical procedures (2)
- Surgical oncology (2)
- Survival (2)
- Sweden (2)
- Teeth (2)
- Tomosynthese (2)
- Trauma (2)
- Ultraschall (2)
- Validation (2)
- Viral load (2)
- Vitamin D (2)
- Vitamin D deficiency (2)
- acute kidney injury (2)
- angiogenesis (2)
- antioxidants (2)
- ataxia telangiectasia (2)
- atherosclerosis (2)
- attention (2)
- bioinformatics (2)
- breast (2)
- cardiac surgery (2)
- catheter ablation (2)
- ceramides (2)
- child (2)
- chronic kidney disease (2)
- connectivity (2)
- cytokines (2)
- data science (2)
- development (2)
- endothelial cells (2)
- epilepsy (2)
- follow‑up (2)
- forensic entomology (2)
- galactography (2)
- galactomosynthesis (2)
- guideline (2)
- hedgehog signaling (2)
- hepatitis C virus (2)
- human (2)
- hyperglycemia (2)
- hypoxia (2)
- imaging (2)
- immunotherapy (2)
- innate immunity (2)
- interleukin-4 (2)
- liver injury (2)
- local recurrence (2)
- lyme disease (2)
- matrix (2)
- medical students (2)
- mesenchymal stromal/stem cells (2)
- metabolism (2)
- miRNA (2)
- microRNA (2)
- minimalinvasive Biopsie (2)
- minimally invasive biopsies (2)
- neoadjuvant chemotherapy (2)
- neoadjuvante Chemotherapie (2)
- next generation sequencing (NGS) (2)
- obesity (2)
- paclitaxel (2)
- predictive factors (2)
- pregnancy (2)
- primary immunodeficiency (2)
- prognostic factors (2)
- psoriasis (2)
- radiation (2)
- rapamycin (2)
- reproducibility (2)
- resistance (2)
- safety (2)
- schizophrenia (2)
- screening (2)
- seizure (2)
- sphingosine 1-phosphate (2)
- spreadsheet (2)
- stationarity (2)
- studies (2)
- surgery (2)
- tobacco prevention (2)
- tomosynthesis (2)
- treatment/therapy (2)
- ultrasound (2)
- vector (2)
- vemurafenib (2)
- workflow (2)
- (surface) partial differential equations (1)
- 1,2-dichloroethane (1)
- 1,25-Dihydroxyvitamin D (1)
- 16p11.2 (1)
- 2-deoxyglucose (2-DG) (1)
- 3D spatio-temporal resolved mathematical models (1)
- 4-FA (1)
- A375 human melanoma cells (1)
- A549 (1)
- ACE-inhibitor (1)
- ACURATE neo (1)
- ADHD (1)
- AIDS (1)
- AKI (1)
- ALK gene (1)
- ALK-rearranged NSCLC (1)
- ARA (1)
- ARFI (1)
- ASO (1)
- ATP-citrate lyase (1)
- Abatacept (1)
- Acoustics (1)
- Activities of daily living (1)
- Acute bronchitis (1)
- Acute cough (1)
- Acute lymphocytic leukaemia (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Adipose-derived mesenchymal stem cells (1)
- Adults (1)
- Aedes aegypti (1)
- Aedes albopictus (1)
- Age (1)
- Age groups (1)
- Aggressive periodontitis (1)
- Akaike information criterion (AIC) (1)
- Aliphatic halogenated hydrocarbons (1)
- Alleles (1)
- Allergic asthma (1)
- Allgemeinmedizin (1)
- Alveolar ridge augmentation (1)
- Ambroxol (1)
- Anatomie (1)
- Anatomie und Histologie (1)
- Andexanet alpha (1)
- Angioedema (1)
- Angiogenesis (1)
- Angioplasty (1)
- Animal wings (1)
- Anomalie <Medizin> (1)
- Antibiotics (1)
- Antibodies (1)
- Antibody-mediated rejection (1)
- Anticoagulant therapy (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Antithrombotic therapy (1)
- Antiviral agents (1)
- Antiviral therapy (1)
- Apixaban (1)
- Apoptosis (1)
- Aquaporins (1)
- Arms (1)
- Ascites (1)
- Aspergillus (1)
- Asphyxia (1)
- Atrial appendage occlusion (1)
- Attention (1)
- Attention-deficit / hyperactivity disorder (1)
- Attitude (1)
- Aurora A (1)
- Austria (1)
- Auto transfusion (1)
- Autoimmunity (1)
- Autopsy (1)
- Axons (1)
- Azathioprine (1)
- B cell subpopulations (1)
- B cells (1)
- B-cell immunology (1)
- B-cell lymphoma (1)
- BATF3 (1)
- BCG-Therapie (1)
- BCR signaling (1)
- BIAM-switch (1)
- BMC (1)
- BPD (1)
- BRCA1 (1)
- BRCA2 (1)
- BTK (1)
- Babesia divergens (1)
- Babesia microti (1)
- Bacterial meningitis (1)
- Bacterial pathogens (1)
- Bayesian inference (1)
- Behavioral analysis (1)
- Benefit (1)
- Best practice (1)
- Bibliometrics (1)
- Bidirectional genes (1)
- Big Data (1)
- Big data (1)
- Big five (1)
- Biofluids (1)
- Bioinformatics (1)
- Biological (1)
- Biological invasion (1)
- Biomechanical analysis (1)
- Biophysical models (1)
- Biopsy (1)
- Biosynthetic mesh (1)
- Bipolar disorder (1)
- Birth weight (1)
- Blasenkarzinom (1)
- Blended learning curriculum · (1)
- Blended-Learning-Curriculum (1)
- Blood cells (1)
- Blood groups (1)
- Blood-brain barrier (1)
- Bloodstream infections (1)
- Blurred vision (1)
- Blutgefäß (1)
- Bone defect (1)
- Bone marrow cells (1)
- Bone marrow fibrosis (1)
- Bone marrow mononuclear cells (1)
- Bone marrow-derived mesenchymal stem cells (1)
- Bone tissue engineering (1)
- Borrelia (1)
- Borrelia burgdorferi (1)
- Borrelia miyamotoi (1)
- Bradykinin (1)
- Brain anatomy (1)
- Brain damage (1)
- Brain ischemia (1)
- Breast tumors (1)
- Bright light therapy (1)
- Bronchial inflammation (1)
- Bronchitis severity scale (1)
- Bronchopulmonary dysplasia (1)
- Burden of disease (1)
- Bypass liner (1)
- C-reactive protein (1)
- C. elegans (1)
- C1 inhibitor (1)
- C1-inhibitor (1)
- C5 acylcarnitine (1)
- CCL2 (1)
- CCN2 (1)
- CD3/19 depletion (1)
- CD34 selection (1)
- CD36 (1)
- CD74 (1)
- CDK4/6 inhibitor (1)
- CHRNA10 (1)
- CHRNA7 (1)
- CHRNA9 (1)
- CNS (1)
- CO2-induced forced ventilation (1)
- COI (1)
- COII (1)
- COMT (1)
- COPD course and therapy (1)
- CRE-luciferase (1)
- CRISPR/Cas9 (1)
- CRM1 (1)
- CTX (1)
- Ca2+ imaging (1)
- Caffeine (1)
- Calcium signalling (1)
- Calnexin (1)
- Cancer detection and diagnosis (1)
- Cancer epidemiology (1)
- Cancer treatment (1)
- Carbon tetrachloride (1)
- Cardiac Fibrosis (1)
- Cardiac surgery (1)
- Cardiac surgery patients (1)
- Cardiomyopathy (1)
- Cardiovascular biology (1)
- Cardiovascular disease (1)
- Cardiovascular genetics (1)
- Cell binding (1)
- Cell cultures (1)
- Cell distribution (1)
- Cell membranes (1)
- Cell salvage (1)
- Cell signalling (1)
- Cementation (1)
- Ceramic (1)
- Cerclage (1)
- Cerebral ischemia (1)
- Cerebrospinal fluid (1)
- Certification (1)
- Cesarean section (1)
- Chaperone (1)
- Chemical biology (1)
- Chemical ecology (1)
- Chemobrain (1)
- Chemoembolization (1)
- Chest pain unit (1)
- Chikungunya virus (1)
- Child (1)
- Children (1)
- Chloroform (1)
- Chondrocytes (1)
- Chromatin accessibility (1)
- Chromatin and Epigenetics (1)
- Chronic heart failure (1)
- Chronic periodontiti (1)
- Chronification (1)
- Circadian rhythms and sleep (1)
- Cleanliness level (1)
- Clinical frailty scale (1)
- Clinical genetics (1)
- Clinical outcome (1)
- Clinical psychometry (1)
- Clinical study (1)
- Clinical trials (1)
- Closure (1)
- Co-culture (1)
- Co-morbidity (1)
- Cocaine (1)
- Cognition (1)
- Cognitive neuroscience (1)
- Colon cancer (1)
- Colon capsule endoscopy (1)
- Comparative effectiveness research (1)
- Complement system (1)
- Complementation rate (1)
- Complete heart block (1)
- Complex I (1)
- Complex II (1)
- Complex hernia (1)
- Complex networks (1)
- Complication management (1)
- Connective tissue (1)
- Consortia (1)
- Conventional synthetic disease-modifying antirheumatic drug (1)
- Coronary artery disease (1)
- Coronary intervention (1)
- Credentialing (1)
- Critical bleeding (1)
- Crohn’s disease (1)
- CspZ (1)
- Curriculum (1)
- Cystic fibrosis (1)
- Cytokines (1)
- Cytology (1)
- DAMP (1)
- DLBCL (1)
- DMARDs (biologic) (1)
- DMARDs (synthetic) (1)
- DNA methylation (1)
- DNA mismatch repair (1)
- DNase1-seq (1)
- DOK1 (1)
- DSM (1)
- DTI (1)
- Dabigatran (1)
- Data acquisition (1)
- Data processing (1)
- Data science (1)
- Data visualization (1)
- Decision making (1)
- Deformation (1)
- Dengue (1)
- Dengue fever (1)
- Dengue virus (1)
- Density equalizing mapping (1)
- Dental implants (1)
- Dental phobia (1)
- Dental training (1)
- Dentition (1)
- Dermatomyositis (1)
- Developmental biology (1)
- Diabetes mellitus (1)
- Diagnosis (1)
- Dichloromethane (1)
- Differentiation (1)
- Digital ethics (1)
- Digital rectal examination (1)
- Digital transformation (1)
- Digitale Ethik (1)
- Digitale Transformation (1)
- Dimer (1)
- Dimers (Chemical physics) (1)
- Direct current electrical stimulation (1)
- Disc herniation (1)
- Dissociative seizures (1)
- Distance to water (1)
- Donor Selection (1)
- Dopamine (1)
- Drug discovery (1)
- Drug interactions (1)
- Drug therapy (1)
- Dual therapy (1)
- E/I-Balance (1)
- EGFL7 (1)
- EMT (1)
- ENCODE-DREAM in vivo Transcription Factor binding site prediction challenge (1)
- ERMS (1)
- Early diagnosis (1)
- Early recurrence (1)
- Edoxaban (1)
- Elderly (1)
- Elective caesarean section (1)
- Elevation (1)
- Ellipsoids (1)
- Emotional recognition (1)
- Endocrine cancer (1)
- Endoscopy (1)
- England (1)
- Ensemble learning (1)
- Enterostomy (1)
- Enterostomy closure (1)
- Enterostomy formation (1)
- Environmental chemistry (1)
- Enzyme kinetics (1)
- Enzyme mechanisms (1)
- Epidemiology (1)
- Epidermal growth factor receptor (1)
- Epidural block (1)
- Epigenetics (1)
- Epileptic seizures (1)
- Epithelial cells (1)
- Epstein-Barr virus (1)
- Epstein–Barr virus (1)
- Equipment (1)
- Ergonomics (1)
- Estradiol (1)
- Europe (1)
- European registry for idiopathic pulmonary fibrosis (eurIPFreg) (1)
- Examination questions (1)
- Exosomes (1)
- Experimental models of disease (1)
- Extinction (1)
- Extracellular matrix (1)
- Extracellular matrix proteins (1)
- Extracorporeal purification (1)
- Eye movements (1)
- FAM134B (1)
- FGFR (1)
- FOXO3a (1)
- FTY720 (1)
- FX06 (1)
- Factor analysis (1)
- Fallbeispiele (1)
- Fatiguesyndrom (1)
- Fear conditioning (1)
- FibroScan (1)
- Fibroblasts (1)
- Fibrosis (1)
- Finite Element Method (1)
- Finite Volumes (1)
- Flaps (1)
- Forensics (1)
- Formation dance (1)
- Frailty (1)
- Frühgeburt (1)
- Functional clustering (1)
- G2A (1)
- GABAergic interneurons (1)
- GLI inhibitors (1)
- GPCR (1)
- GSK3α (1)
- GSK3β (1)
- Games (1)
- Gamma-Band Activity (1)
- Gap junctions (1)
- Gastric cancer (1)
- Gastrointestinal cancer (1)
- Gastrointestinal tract (1)
- Gebärmutterhalskrebs (1)
- Gender gap (1)
- Gene Regulation (1)
- Gene expression (1)
- Gene fusion (1)
- Gene microarray analysis (1)
- Gene therapy (1)
- General dental practice (1)
- Generation time (1)
- Geographically weighted regression (GWR) (1)
- German people (1)
- Gestational age (1)
- Glaucoma (1)
- Glioblastoma (1)
- Glycosphingolipids (1)
- Grafts (1)
- Gram negative bacteria (1)
- Greater tuberosity fractures (1)
- Growth factors (1)
- HACA (1)
- HBV reactivation (1)
- HCV treatment (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HER2/neu (1)
- HH (1)
- HIV serodiagnosis (1)
- HIV-1 (1)
- HLA class II (1)
- HLA peptidome (1)
- HMGB1 (1)
- HPV (1)
- HRas (1)
- Haematoma expansion (1)
- Haemostatics (1)
- Hashimoto’s thyroiditis (1)
- Hausarztmangel (1)
- Head injury (1)
- Health care resource utilization (1)
- Health economics (1)
- Health information (1)
- Health risk analysis (1)
- Health-seeking behaviour (1)
- Heart transplantation (1)
- Hedgehog pathway (1)
- Helpline (1)
- Hematocrit value (1)
- Hematopoietic stem cell transplantation (1)
- Hemodynamics (1)
- HepG2 (1)
- Hepatitis B virus (1)
- Hepatitis C (1)
- Hepatitis C virus (1)
- Hepatitis C, Chronic (1)
- Herbalife (1)
- Hereditary breast and ovarian cancer (1)
- HhAntag (1)
- High-intensity interval endurance training (1)
- Hindu Kush Himalayas (1)
- Hip (1)
- Histology (1)
- Histone post-translational modifications (1)
- Homeostasis (1)
- Horner's syndrome (1)
- Horses (1)
- HuR (1)
- Human behaviour (1)
- Human prostate (1)
- Hydroxychloroquine (1)
- Hydroxycut (1)
- Hydroxyurea (1)
- Hypoxia inducible factor (1)
- Hysterektomie-Prävalenz (1)
- IFN (1)
- IL-18BP (1)
- IL-1β (1)
- IL-6 (1)
- IRES translation (1)
- ITGA7 (1)
- IVA interference tandem mass spectrometry (1)
- Iceland (1)
- Idarucizumab (1)
- Idiopathic pulmonary fibrosis (IPF) (1)
- Imaging (1)
- Imaging in LGG (1)
- Immune suppression (1)
- Immunosenescence (1)
- Immunotherapy (1)
- Implementation (1)
- Incisional hernia (1)
- Incomplete colonoscopy (1)
- Indirect-binding (1)
- Induced sputum (1)
- Infectious disease epidemiology (1)
- Inflammatory diseases (1)
- Injuries (1)
- Injury (1)
- Insulin (1)
- Intensive care outcome (1)
- Intensive care units (1)
- Interferon-frei (1)
- Interleukin-6 (1)
- Interspecific competition (1)
- Interstitial lung diseases (ILD) (1)
- Intervertebral disc degeneration (1)
- Intra-abdominal infection (1)
- Intracellular pathogens (1)
- Intracerebral haemorrhage (1)
- Intracranial haemorrhage (1)
- Intracranial hemorrhage (1)
- Intragastric balloon (1)
- Inzidenzkorrektur (1)
- Irregular vaccination (1)
- Italy (1)
- Ivor Lewis esophagectomy (1)
- JNK3 (1)
- Jaw (1)
- Jumping (1)
- KAP (1)
- KDIGO (1)
- Kaisidis plate (1)
- Kidney Transplantation (1)
- Kidney transplant recipients (1)
- Knowledge (1)
- Krebsforschung (1)
- Kupffer cells (1)
- Kynurenine (1)
- LCH (1)
- Labor and delivery (1)
- Lactic acidosis (1)
- Landarztprogramm (1)
- Langerhans cell histiocytosis (1)
- Language (1)
- Laparostomy (1)
- Laterality (1)
- Lebensqualität (1)
- Leberzirrhose (1)
- Lectin affinity plasmapheresis (1)
- Leflunomide (1)
- Legs (1)
- Lernerfolgsmessung (1)
- Lesions (1)
- Leukocyte elastase (1)
- Light sheet fluorescence microscopy (1)
- Linear regression analysis (1)
- Lipidol (1)
- Lipopolysaccharide-binding protein (1)
- Liver cirrhosis (1)
- Liver transplantation (1)
- Livestock (1)
- LncRNA (1)
- Local climate (1)
- Local control (1)
- Locomotor circuit (1)
- Low volume prep (1)
- Low-grade glioma (1)
- Luciferase (1)
- Lumbar spine (1)
- Lung adenocarcinoma (1)
- Lymphom (1)
- Lymphozyt (1)
- Lysosome (1)
- MDR1 (1)
- MEIS2 (1)
- MET (1)
- MOLLI (1)
- MR spectroscopy (1)
- MR-proADM (1)
- MRP4 (1)
- Machine learning (1)
- Macrophages (1)
- Malaria (1)
- Mammalian target of rapamycin (1)
- Marburg virus (1)
- Maternal morbidity (1)
- Maxillary sinus (1)
- Medical communication (1)
- Medical ethics (1)
- Medical hypoxia (1)
- Medical imaging (1)
- Medical risk factors (1)
- Medical traineeship (1)
- Medication Appropriateness Index (1)
- Medication changes (1)
- Medizinische Abbildung (1)
- Medizinische Ausbildung (1)
- Medizinstudierende (1)
- Medizinstudium (1)
- Membrane proteins (1)
- Membrane staining (1)
- Mentor (1)
- Mesangial cells (1)
- Mesh (1)
- Mesh repair (1)
- Messenger RNA (1)
- Metabolic syndrome (1)
- Methotrexate (1)
- Micro RNAs (1)
- Micro-CT (1)
- Microalgae (1)
- Microbial mutation (1)
- Microbiome (1)
- Microsatellite instability (1)
- Middle East respiratory syndrome coronavirus (1)
- Midline laparotomy (1)
- Minimal core of imaging (1)
- Minimal invasive (1)
- Mitochondria (1)
- Mitochondrial ROS (1)
- Mitochondrial disorder (1)
- Mitochondrial proteins (1)
- Mitochondrial respiration (1)
- MitraClip (1)
- Model Organism (1)
- Molecular genetics (1)
- Molecular medicine (1)
- Monocytes and macrophages (1)
- Monolithic crown (1)
- Monte Carlo method (1)
- Morphogenesis (1)
- Mortalitätskorrektur (1)
- Motor skills (1)
- Mountain (1)
- Mouse (1)
- Mouse model (1)
- Mouse models (1)
- Moviprep (1)
- Multi-modal feedback (1)
- Multidisciplinary management (1)
- Multidrug resistance (1)
- Multiple sclerosis (1)
- Multivariate analysis (1)
- Muscle tissue (1)
- Musician-specific seating position (1)
- Myalgia (1)
- Myelofibrosis (1)
- Myocardial infarction (1)
- Myocardial revascularization (1)
- N-Acetylaspartate (1)
- N-acetylcysteine (1)
- N-methyl-D-aspartate receptor (1)
- NAFLD (1)
- NASH (1)
- NDNF interneurons (1)
- NDUFA6 (1)
- NK cells (1)
- NKG2A blocking (1)
- NKG2D (1)
- NK cells (1)
- NOD2 (1)
- NSTEMI (1)
- Nanoparticles (1)
- Natriuretic peptide (1)
- Necrosis (1)
- Necrotizing enterocolitis (1)
- Needs assessment [MeSH] (1)
- Negative staining (1)
- Neoadjuvant therapy (1)
- Neonatal (1)
- Neonatal intensive care unit (1)
- Neonatal morbidity (1)
- Nephrons (1)
- Nerve regeneration (1)
- Nerves (1)
- Neural circuits (1)
- Neurobiology of disease and regeneration (1)
- Neurodevelopment (1)
- Neuroendocrine cancer (1)
- Neuroimaging (1)
- Neutropenia (1)
- Next generation sequencing (1)
- Nfe2l2 (1)
- Niche differentiation (1)
- Nimotuzumab (1)
- Nitric oxide (1)
- Non-interventional study (1)
- Non-responder (1)
- Non-small-cell lung cancer (1)
- Non-trauma (1)
- Noncoding RNA (1)
- Normal distribution (1)
- Nox1 (1)
- Nox4 (1)
- NoxO1 (1)
- Nucleus pulposus cells (1)
- Nutrition (1)
- Nymphs (1)
- OCT (1)
- Observational studies (1)
- Obstetrics and gynecology (1)
- Ocular findings (1)
- Oesophageal cancer (1)
- Okinawa (1)
- Okinawa diet (1)
- Older adults (1)
- Oncologic surgery (1)
- Open abdomen (1)
- Optic nerve atrophy (1)
- Optogenetics (1)
- Oral and maxillofacial trauma (1)
- Oral anticoagulation (1)
- Oral surgery (1)
- Ordinary least squares (OLS) (1)
- Organ dysfunction (1)
- Organ dysfunctions (1)
- Organ support (1)
- Organs at Risk (1)
- Oroantral (1)
- Osimertinib (1)
- Osteogenic differentiation (1)
- Outcome assessment (1)
- Outcome assessment [MeSH] (1)
- OxyELITE Pro (1)
- P-gp (1)
- P1NP (1)
- P2X7 receptor (1)
- PAH (1)
- PAI-1 (1)
- PBX1 (1)
- PC12 cells (1)
- PCV (1)
- PD-L1 (1)
- PEGylated PLGA (PLGA-PEG) (1)
- PFL (1)
- PI3K (1)
- PKA (1)
- PTCH (1)
- PTDM (1)
- PTK2B (1)
- Pacemaker (1)
- Pain (1)
- Pancreatitis (1)
- Parkin (1)
- Parkinson disease (1)
- Pathological complete response (1)
- Pathology (1)
- Patient Blood Management (1)
- Patient Outcome Assessment (1)
- Patient satisfaction (1)
- Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (1)
- Pediatrics [MeSH] (1)
- Peer Teaching (1)
- Peer teaching (1)
- Periodontal diseases (1)
- Peritonitis (1)
- Personality (1)
- Personalized medicine (1)
- Pessar (1)
- Pharmacy setting (1)
- Pharyngeal reflex (1)
- Phospho-soda (1)
- Phospholipids (1)
- Phosphorylation (1)
- Phylogenetic analysis (1)
- Physical environment (1)
- Physicians (1)
- Physiology (1)
- PillCamColon2 (1)
- Polyps (1)
- Portal hypertension (1)
- Position paper (1)
- Post-transplant (1)
- Postoperative infections (1)
- Posttranslational modification (1)
- Postural control (1)
- Poverty (1)
- Practice (1)
- Preclinical (1)
- Pregnancy (1)
- Preterm birth (1)
- Primary health care (1)
- Progesteron (1)
- Progesterone (1)
- Prognostic markers (1)
- Programming languages (1)
- Progranulin (1)
- Proliferation (1)
- Prostate Cancer (1)
- Prostate cancer cell lines (1)
- Prosthetic rehabilitation (1)
- Protein domains (1)
- Protein translation (1)
- Proteins (1)
- Prothrombin complex concentrate (1)
- Prüfungsfragen (1)
- Psychiatric disorders (1)
- Psychology (1)
- Public and occupational health (1)
- Pulmonary artery pressure (1)
- Pulmonary embolism (1)
- Pyruvate (1)
- Qualitative research [MeSH] (1)
- Quality of health care [MeSH] (1)
- Quality of life (1)
- Quantitative MRI (1)
- Quantitative trait loci (1)
- Questionnaires (1)
- Quinolinate phosphoribosyltransferase (1)
- Quinolinic acid (1)
- RNA therapy (1)
- RNA viruses (1)
- ROS (1)
- Rab7 (1)
- Radical nephrectomy (1)
- Rainfall (1)
- Randomized (1)
- RapL (1)
- Rapamycin (1)
- Rare diseases (1)
- Re-exploration (1)
- Rearing temperature (1)
- Red blood cell transfusion (1)
- Redox modification (1)
- Regeneration (1)
- Regression analysis (1)
- Regulatory networks (1)
- Reintervention (1)
- Remote monitoring (1)
- Renal cancer (1)
- Renal system (1)
- Research Article (1)
- Research architecture (1)
- Resource competition (1)
- Respiratory tract diseases (1)
- Response criteria (1)
- Resuscitation (1)
- Retinal degeneration (1)
- Rheumatoid arthritis (1)
- Rivaroxaban (1)
- Rural area (1)
- Ruxolitinib (1)
- S1P (1)
- SAVI (1)
- SCMR (1)
- SDH (1)
- SKAP1 (1)
- SMAD signaling (1)
- SOFA (1)
- STING (1)
- Safety equipment (1)
- Safety learning (1)
- Sarcoidosis (1)
- Scientific publishing (1)
- Secretion (1)
- Senescence (1)
- Sensitivity (1)
- Sensory Neuroscience (1)
- Sensory processing (1)
- Septic shock (1)
- Sequence alignment (1)
- Serum (1)
- Severe blood loss (1)
- Severity of illness index (1)
- Sex differences (1)
- Shannon index (1)
- Sholl analysis (1)
- Simulated patients (1)
- Single-cell RNA-seq (1)
- Smac mimetic (1)
- Small molecules (1)
- Small-cell lung cancer (1)
- Smart nebulizer (1)
- Smoking habits (1)
- Social communication (1)
- Social research (1)
- Social sciences (1)
- Solidworks 2015 (1)
- Sphingolipids (1)
- Spine Register (1)
- Spirochetes (1)
- Sports (1)
- Sports and exercise medicine (1)
- Spot sign (1)
- Standards of care (1)
- Starvation (1)
- Statistical data (1)
- Statistical methods (1)
- Status epilepticus (1)
- Stenotrophomonas maltophilia (1)
- Stereotactic radiosurgery (1)
- Stoma (1)
- Streptococcus pneumoniae (1)
- Stringed bow player (1)
- Structural MRI (1)
- Structural genomics (1)
- Study protocol (1)
- Suicide (1)
- Sulfasalazine (1)
- Sumatra (1)
- Supraspinatus tendon (1)
- Surgical ICU (1)
- Surgical site occurrence (1)
- Survival analysis (1)
- Survival data (1)
- Sweat osmolality (1)
- Sweat secretion rate (1)
- Syncope (1)
- Synthetic (1)
- T cell (1)
- T cells (1)
- T helper 17 cells (1)
- T-DM1 (1)
- T-cell targeting (1)
- T-cells (1)
- T1 mapping (1)
- TALE-homdomain protein (1)
- TAVR (1)
- TBSS (1)
- TC stenosis (1)
- TF-complexes (1)
- TMS-EEG (1)
- TNF inhibitors (1)
- TNF-α (1)
- TOR inhibitor (1)
- TP53 mutation status (1)
- Targeted therapy (1)
- Taxonomy (1)
- Technique (1)
- Telemedicine (1)
- Temporal lobe epilepsy (1)
- Term birth (1)
- Testosterone (1)
- Tet-inducible system (1)
- Thailand (1)
- Thermoregulation (1)
- Three-dimensional back scan (1)
- Thrombosis (1)
- Thyroid (1)
- Tick-Borne diseases (1)
- Tick-borne encephalitis (1)
- Timing (1)
- Tinnitus (1)
- Tomography (1)
- Tooth transplantation (1)
- Torque (1)
- Toxicity (1)
- Training (1)
- Tranexamic acid (1)
- Transcription (1)
- Transcription Factors (1)
- Transcription factors (1)
- Transferases (1)
- Transfusion (1)
- Transgenic SK-2 mice (1)
- Trauma surgery (1)
- Traumatic brain injury (1)
- Traumatic injury (1)
- Treatment (1)
- Trichuris suis ova (1)
- Triple negative (1)
- Triple therapy (1)
- Triple-negative breast cancer (1)
- Troponin (1)
- Tubers (1)
- Tumor infiltrating lymphocytes (1)
- Tumour biomarkers (1)
- Type 2 diabetes (1)
- UDP-glucose ceramide glycosyltransferase (1)
- UGCG (1)
- ULBP4 (1)
- UWB diagnostics (1)
- Ubiquitin (1)
- Ubiquitination (1)
- Ultra microscopy (1)
- Ultrasonic nebulizer (1)
- Ultrasound imaging (1)
- Upper body posture (1)
- Usutu virus (1)
- V4 (1)
- VEGF (1)
- VIP1 (1)
- Vaccination breakthrough (1)
- Vaccine (1)
- Vascular emergencies (1)
- Vector mosquito (1)
- Viral core (1)
- Viral replication (1)
- Vision (1)
- Visual acuity (1)
- Vitamin (1)
- Volumetric analysis (1)
- Vorklinik (1)
- Warburg effect (1)
- Water chemistry (1)
- Weight loss (1)
- West Nile fever (1)
- West Nile neuroinvasive disease (1)
- West Nile virus (1)
- Work shadowing (1)
- Working memory (1)
- X-ray crystallography (1)
- XL probe (1)
- Yarrowia lipolytica (1)
- Zervixverkürzung (1)
- Zika (1)
- Zika vaccine (1)
- Zika virus (1)
- Zirconia (1)
- Zoopotentation (1)
- Zooprophylaxis (1)
- abemaciclib (1)
- abnormal tumor vasculature (1)
- accident (1)
- acetaminophen (1)
- acetyl-CoA (1)
- activation receptors (1)
- active/deactive transition (1)
- actography (1)
- acute cholecystitis (1)
- acute coronary syndrome (1)
- acute exacerbations of COPD (1)
- acute inflammation (1)
- acute myeloid leukemia (1)
- adaptation (1)
- adenosine receptors (1)
- adherence (1)
- adhesion (1)
- adipose-derived mesenchymal stem cells (1)
- adoptive cell therapy (1)
- adoptive immunotherapy (1)
- advanced breast cancer (1)
- adverse reaction (1)
- aerosol (1)
- aggression (1)
- airway remodeling (1)
- aliphatic halogenated hydrocarbons (1)
- alirocumab (1)
- allergen immunotherapy (1)
- allergic rhinitis (1)
- allogeneic stem cell transplantation (1)
- alpinia zerumbet (1)
- anaesthesia in orthopaedics (1)
- anaesthetics (1)
- anastomotic leakage (1)
- anatomy (1)
- anatomy and histology (1)
- anti-GD2 immunotherapy (1)
- anti-inflammatory (1)
- antibiotic (1)
- antibiotic therapy (1)
- antibodies (1)
- anticonvulsants (1)
- antihormone therapy (1)
- antimicrobial activity (1)
- antioxidant (1)
- antioxidant activity (1)
- antisense oligonucleotides (1)
- aortic stenosis (1)
- apoptosis (1)
- apps (1)
- aptamer (1)
- aquaporin 1 (1)
- arachidonate 15-lipoxygenase (1)
- arachidonic acid (1)
- ascites (1)
- asthma (1)
- atrial fibrillation (1)
- atrial septostomy (1)
- atrophy (1)
- autoimmunity (1)
- autologous stem cell transplantation (1)
- avelumab (1)
- back scan (1)
- bacterium (1)
- balanced state (1)
- basal cell carcinoma (1)
- basic leucine zipper transcription factor ATF-like (1)
- beta blockade (1)
- betamethasone dipropionate (1)
- bevacizumab (1)
- bibliometric analysis (1)
- bibliometry (1)
- bio imaging (1)
- bioactive phytochemicals (1)
- bioluminescence (1)
- biomarker (1)
- biopsy (1)
- bipolar disorders (1)
- birch pollen allergoid (1)
- blood (1)
- blood donor (1)
- blow flies (1)
- blow fly (1)
- body posture (1)
- borrelia (1)
- brachytherapy (1)
- bronchodilator (1)
- buccal mucosa (1)
- cAMP (1)
- cFLIP (1)
- calcification score (1)
- calcipotriol (1)
- calcium-independent phospholipase A2β (1)
- cancer stem cells (1)
- carbon tetrachloride (1)
- cardiovascular diseases (1)
- cardiovascular precision medicine (1)
- caspase-2 (1)
- ceRNA (1)
- celery (1)
- cell biology (1)
- cell cycle (1)
- cell migration (1)
- cellular signalling (1)
- centenarians (1)
- cerclage (1)
- cerebrospinal fluid (1)
- cervical cancer (1)
- cervical shortening (1)
- cervical spine (1)
- cervico-thoracic junction (1)
- ch14.18/CHO (1)
- chamomile (1)
- checkpoint inhibition (1)
- chemokine (1)
- chemotaxis (1)
- chemotherapeutic drug resistance (1)
- child abuse and neglect (1)
- child maltreatment (1)
- children (1)
- cholangiocarcinoma (1)
- cholesterol (1)
- chromosomal integration (1)
- cilia (1)
- circadian rhythms (1)
- circadian variation (1)
- cisplatin resistance (1)
- clinical management (1)
- clinical practice (1)
- clinical trial (1)
- cognition (1)
- cognitive states (1)
- cohort study (1)
- colitis (1)
- collagen (1)
- collagen-based biomaterial (1)
- collective dynamics (1)
- colon (1)
- colon carcinoma cells (1)
- column chromatography (1)
- combination (1)
- combination therapy (1)
- combined immunodeficiency (1)
- complement dependent cytotoxicity (1)
- complementary information (1)
- complex I (1)
- complexome profiling (1)
- complications (1)
- computational virology (1)
- computer-assisted drug therapy (1)
- congenic mice (1)
- contact lens solution (1)
- continuous glucose monitoring (1)
- controlled nuclear import (1)
- coronary (1)
- coronary disease (1)
- correction of incidence rate (1)
- correction of mortality rate (1)
- corrosion (1)
- criticality (1)
- cryoballoon (1)
- cumulative dose (1)
- curriculum (1)
- cytarabine dose (1)
- cytochrome P450 2E1 (1)
- cytokine release syndrome (1)
- cytokine-induced killer cells (1)
- cytotoxic T cells (1)
- dabrafenib (1)
- damage associated molecular pattern (1)
- decision aids (1)
- delayed cholecystectomy (1)
- delta-9-tetrahydrocannabinol (1)
- dendritic cells (1)
- dendritic inhibition (1)
- dental abutment (1)
- dental implants (1)
- dermatology (1)
- dexamethasone (1)
- diabetes (1)
- diabetic macular edema (1)
- diagnostics (1)
- dietary supplements (1)
- differentiated thyroid carcinoma (1)
- differentiation (1)
- diffuse low-grade glioma (1)
- digital age determination (1)
- dihydroceramides (1)
- diplopia (1)
- direct-acting antivirals (1)
- disease progression (1)
- disintegration (1)
- dose response curve (1)
- doxorubicin (1)
- doxycycline (1)
- drug interaction (1)
- drug release (1)
- drug-coated balloon (1)
- drug-eluting balloon (1)
- dynamic stimuli (1)
- eNPP2 (1)
- early cholecystectomy (1)
- educational cases (1)
- educational measurement (1)
- efficacy (1)
- elderly (1)
- embodiment (1)
- emulsion diffusion (1)
- encoding (1)
- endogenous clock (1)
- endoplasmic reticulum (1)
- endothelial activation (1)
- endothelial barrier (1)
- endothelial cell (1)
- endothelial nitric-oxide synthase (1)
- epidemics (1)
- epidemiology (1)
- epileptic encephalopathies (1)
- event-based (1)
- excitability (1)
- exercise (1)
- exosomes (1)
- exponential model (1)
- extracting solvents (1)
- fMRI (1)
- face (1)
- facial EMG (1)
- facial emotion recognition (1)
- facial expressions of emotion (1)
- facial muscle activity (1)
- factor H (1)
- falls (1)
- false memory (1)
- fear learning (1)
- female subjects (1)
- femoropopliteal segment (1)
- fibrinolysis (1)
- fibrosis (1)
- flow cytometry (1)
- fluocinolone acetonide (1)
- focal adhesion (1)
- forensics (1)
- functional connectivity (1)
- functional genomics (1)
- functional magnetic resonance imaging (fMRI) (1)
- fungus (1)
- galactomannan (1)
- gallstone disease (1)
- gastric cancer (1)
- gastro-oesophageal junction cancer (1)
- gene delivery (1)
- gene therapy (1)
- gene vectors (1)
- general anaesthesia (1)
- general practice (1)
- genetic markers (1)
- geriatric medicine (1)
- germinal center (1)
- glioma (1)
- glioma-associated oncogene homolog (1)
- gliomas (1)
- global mapping (1)
- glucocorticoid (1)
- glucose metabolism (1)
- glycolysis (1)
- graft perfusion (1)
- graft rejection (1)
- graft-versus-host disease (1)
- graft-versus-tumor effect (1)
- granulocytemacrophage colony-stimulating factor (1)
- granulomas (1)
- granulomatous inflammation (1)
- green tea extract (1)
- hanging donors (1)
- head and neck squamous cell carcinoma (1)
- head-and-neck cancer (1)
- headache (1)
- health (1)
- health care personnel (1)
- health information exchange (1)
- health services accessibility (1)
- health-related quality of life (1)
- heart failure (1)
- hedgehog signaling pathway (1)
- helminths (1)
- hematopoietic stem cells (1)
- hepatitis B virus (1)
- hepatitis C virus (HCV) (1)
- hepatitis E virus (1)
- hepatocyte transplantation (1)
- hereditary angioedema (1)
- hierarchy (1)
- hippocampal neuronal cell line (1)
- histone acetylation (1)
- histone deacetylase (1)
- histone deacetylase 5 (1)
- host-targeting antivirals (1)
- human biology and medicine (1)
- human papilloma virus (1)
- human renal proximal tubular epithelial cells (1)
- humanized mouse (1)
- humans (1)
- humoral factors (1)
- hybrid (1)
- hydrocephalus (1)
- hydroxyapatite crystals (1)
- hyperbaric oxygen treatment (1)
- hyperlipidemia (1)
- hypothalamus (1)
- hypoxia-induced cell death (1)
- imitation (1)
- immune (1)
- immune reconstitution (1)
- immunohistochemistry (1)
- in-cabin exposure (1)
- inducible gene expression (1)
- infectivity (1)
- inflammasome (1)
- influenza (1)
- influenza vaccine (1)
- information decomposition (1)
- inhaler (1)
- innate lymphoid cells (1)
- insulin resistance (1)
- integration (1)
- integrin (1)
- integrins (1)
- interferon (1)
- interferon gamma (1)
- interleukin-1 (1)
- interleukin-18 (1)
- interleukin-1β (1)
- interleukin-23 receptor (1)
- interneurons (1)
- interstitial brachytherapy (1)
- intervertebral disc degeneration (1)
- intestinal graft-versushost disease (1)
- intracellular trafficking (1)
- intraperitoneal therapy (1)
- intraventricular chemotherapy (1)
- invasion (1)
- ionomycin (1)
- irradiation (1)
- ischemic type biliary lesions (1)
- isocaloric ketogenic diet (1)
- isovaleric acidaemia (1)
- kavalactones (1)
- keratinocytes (1)
- kinase inhibitor (1)
- knockout mice (1)
- knowledge discovery (1)
- laceration (1)
- lapatinib (1)
- late lumen loss (1)
- layer 1 (1)
- leptomeningeal metastases (1)
- levetiracetam (1)
- lipoxygenase (1)
- liver cirrhosis (1)
- liver fibrosis (1)
- liver transplantation (1)
- long-acting muscarinic antagonist (1)
- long-term follow-up (1)
- long-term infusion (1)
- longevity (1)
- lung cancer (1)
- lung remodeling (1)
- lung transplantation (1)
- lymphocyte (1)
- lymphoma (1)
- mTOR (1)
- mTOR inhibitor (1)
- mTORC1 (1)
- machine-learning (1)
- macula (1)
- magnetoencephalography (1)
- maintenance (1)
- malignancy (1)
- marginal bone loss (1)
- markovianity (1)
- massively parallel multigrid solvers (1)
- maternal care (1)
- mathematical modeling (1)
- measure development/validation (1)
- mechanobactericidal surfaces (1)
- medical illustration (1)
- medical school (1)
- medication reconciliation (1)
- memebrane (1)
- mentoring (1)
- metabolic cancer therapy (1)
- metamorphosis (1)
- metastatic (1)
- methotrexate (1)
- methyltransferases (1)
- miR-122 (1)
- miR-21 (1)
- microdosing (1)
- microsaccades (1)
- microsatellite instability (1)
- microwave breast imaging (1)
- migrants (1)
- migration (1)
- mitochondrial disease (1)
- mobile air quality study (1)
- moisturing cream (1)
- molecular identification (1)
- molecular mechanisms (1)
- momilactone A (1)
- momilactone B (1)
- monkey (1)
- mouse (1)
- multidrug resistance (1)
- multimorbidity (1)
- multinucleated giant cells (1)
- multiple chronic conditions (1)
- multiple myeloma (1)
- multiple sclerosis (1)
- multisite cooperation (1)
- myocyte enhancer factor 2 (1)
- nanostructures (1)
- natural killer T cells (1)
- natural killer cell (1)
- neocortical circuits (1)
- neoepitopes (1)
- neonatal intensive care unit (1)
- neonate (1)
- neural network (1)
- neural oscillations (1)
- neuraminidase inhibitor (1)
- neuro-ophthalmological examination (1)
- neuroblastoma (1)
- neurocognition (1)
- neurocritical care (1)
- neurogenesis (1)
- neurological emergencies (1)
- neuromodulation (1)
- neurophysiology (1)
- neuropilin-1 (1)
- nitric oxide (1)
- nitro-fatty acids (1)
- non-ST-segment elevation acute coronary syndrome (1)
- nonalcoholic fatty liver disease (1)
- nonalcoholic steatohepatitis (1)
- nonviral gene delivery (1)
- novel psychoactive substance (1)
- nursery school students (1)
- nursery schools (1)
- nursery students (1)
- nurses (1)
- obese (1)
- object tracking (1)
- omega-3 fatty acids (1)
- oncogene (1)
- one health (1)
- open-source (1)
- oral kallikrein inhibitor (1)
- orthopic liver transplantation (1)
- oscillations (1)
- oseltamivir (1)
- ostium (1)
- outcome (1)
- outcomes (1)
- ovarian cancer (1)
- oxygen (1)
- p21-activated kinase 2 (1)
- p38 (1)
- p97 (1)
- pCREB (1)
- palbociclib (1)
- palmitoylation (1)
- papilloma (1)
- parameter estimation (1)
- parsley (1)
- particle size distribution (1)
- particulate matter (1)
- patency (1)
- patient study (1)
- patients (1)
- pentose phosphate pathway (1)
- pericytes (1)
- peripheral artery disease (1)
- peripheral vascular diseases (1)
- peritoneal carcinomatosis (1)
- persistent atrial fibrillation (1)
- persisting pain (1)
- personalized oncology (1)
- pertuzumab (1)
- pessary (1)
- pharmacology (1)
- phase III (1)
- phase-1 (1)
- phenolics (1)
- phenylephrine (1)
- phosphate (1)
- photoaging (1)
- physical activity (1)
- physical activity promotion (1)
- physical activity recommendations (1)
- pictilisib (1)
- pig (1)
- pivalate (1)
- pivoloyl (1)
- plasminogen (1)
- platform-switched (1)
- polarization (1)
- poly(I:C) (1)
- poly(lactic-co-glycolic acid) (PLGA) (1)
- polydipsia (1)
- polylactic acid (PLA) (1)
- polymerase chain reaction (1)
- polypharmacy (1)
- polyphenols (1)
- polytrauma (1)
- polyuria (1)
- popliteal artery (1)
- porcine (1)
- post-transplantation lymphoproliferative disease (1)
- posttranslational modification (1)
- pre-emptive allogeneic hematopoietic stem cell transplantation (1)
- preclinical semesters (1)
- preconditioning (1)
- pressure (1)
- pressurized intraperitoneal aerosol chemotherapy (PIPAC) (1)
- preterm (1)
- preterm birth (1)
- pretreatment (1)
- prevalence of hysterectomy (1)
- prevent smoking (1)
- primary cilium (1)
- primary healthcare (1)
- primary mouse proximal tubular cells (1)
- progesterone (1)
- programmed cell death ligand 1 (1)
- programmed cell death protein 1 (1)
- proliferation (1)
- prophylaxis (1)
- propofol anesthesia (1)
- prospective memory (1)
- prostaglandin E2 (1)
- prostate cancer (1)
- protein kinase D (1)
- protein kinases (1)
- proteomics (1)
- pruritus (1)
- psoriatic arthritis (1)
- psychological questionnaires (1)
- psychometric properties (1)
- publication (1)
- pulmonary arterial hypertension (1)
- pulmonary inflammation (1)
- pulmonary vein isolation (1)
- qPCR (1)
- qRT-PCR (1)
- qualitative research (1)
- quality control (1)
- radical scavenging chemicals (1)
- radiofrequency (1)
- radiotherapy (1)
- radiotherapy resistance (1)
- rare diseases (1)
- rat (1)
- real-world evidence (1)
- realistic geometries (1)
- redox signalling (1)
- redox-linked proton translocation (1)
- redundancy (1)
- redundant information (1)
- reference values (1)
- regulatory T cell (1)
- relapsing–remitting (1)
- reliability (1)
- remote ischemic preconditioning (1)
- renal cell cancer (1)
- renal cell carcinoma (1)
- renal failure (1)
- renal ischemia reperfusion injury (1)
- research consortium (1)
- resilience (1)
- respiratory complex I (1)
- restenosis (1)
- restrictive atrial communication (1)
- retina (1)
- retinoic acid-related orphan receptor gamma t (1)
- rhodocetin-αβ (1)
- rhythm (1)
- ribociclib (1)
- rice husk (1)
- risk assessment (1)
- rural health program (1)
- saliva (1)
- school-based prevention (1)
- scientometrics (1)
- scientometry (1)
- screening routine (1)
- secretion (1)
- selection (1)
- selective attention (1)
- selective mutism, (1)
- semen (1)
- sensitization (1)
- sensory neurons (1)
- sequential ALK-inhibitor therapy (1)
- shedding (1)
- shell ginger (1)
- shortage of family doctors (1)
- siRNA (1)
- signaling (1)
- silence interfering RNA (1)
- sirtuin1 (1)
- sirtuins (1)
- skeletal muscle (1)
- skin (1)
- smoking (1)
- smoking cessation (1)
- solvent displacement (1)
- somatostatin interneurons (1)
- sonidegib (1)
- spatial (1)
- sphinganine 1-phosphate (1)
- sphingosine kinase 1 (1)
- spinster homology protein 2 (Spns2) (1)
- spirochetes (1)
- squamous cell carcinoma (1)
- standard value (1)
- stem cell niche (1)
- stem cells (1)
- stenosis (1)
- stenosis quantification (1)
- sterol regulatory element binding protein-2 (1)
- stroke (1)
- structural biology and molecular biophysics (1)
- subcutaneous immunotherapy (1)
- sublingual immunotherapy (1)
- subventricular zone (1)
- superficial femoral artery (1)
- syncope (1)
- synergy (1)
- tear (1)
- temozolomide (1)
- temperature (1)
- temsirolimus (1)
- testicular cancer (1)
- tetracycline (1)
- tetrahydrobiopterin (1)
- thymus (1)
- titanium (1)
- titanium particles (1)
- tobacco (1)
- tobacco cessation (1)
- tomography (1)
- top-down processing (1)
- topical agent (1)
- total events (1)
- total flavonoids (1)
- total phenols (1)
- toxicity (1)
- tracking (1)
- traffic emissions (1)
- transcatheter aortic valve replacement (1)
- transcranial magnetic stimulation (1)
- transcriptome analysis (1)
- transfemoral (1)
- transgelin (1)
- transient elastography (1)
- transiente Elastographie (1)
- transketolase-like protein 1 (1)
- translational cancer research (1)
- transposition (1)
- trastuzumab (1)
- trauma (1)
- trehalose (1)
- tubular regeneration (1)
- tumor metabolism (1)
- tumor-infiltrating lymphocytes (1)
- type B (1)
- ubiquitin (1)
- unique information (1)
- upper gastrointestinal cancer (1)
- vaccination rates (1)
- vaccine (1)
- vaccine acceptance (1)
- vaccine trial (1)
- validity (1)
- vascular calcification (1)
- vascular endothelial growth factor receptor 2 (1)
- vascular smooth muscle cells (1)
- vasculogenic mimicry (1)
- vasoconstriction (1)
- vasodilation (1)
- vasopressin (1)
- ventilation modes (1)
- ventral striatum (1)
- ventriculoperitoneal shunt (1)
- vesicular glutamate transporter 2 (1)
- vessel-associated mural cells (1)
- videos (1)
- viral dynamics (1)
- virus (1)
- virus-like particles (1)
- vision (1)
- vismodegib (1)
- vismodegib (GDC-0449) (1)
- visual cortex (1)
- visuo-spatial attention (1)
- vitamin D (1)
- vitamin D receptor (1)
- wear (1)
- white-matter (1)
- wild animals (1)
- willingness to participate (1)
- within-host viral modelling (1)
- working memory (1)
- wound healing (1)
- yield optimization (1)
- ß-D-glucan (1)
- α-mannosidosis (1)
Institute
- Medizin (472)
- Präsidium (14)
- Sonderforschungsbereiche / Forschungskollegs (14)
- Exzellenzcluster Makromolekulare Komplexe (9)
- Biowissenschaften (8)
- Sportwissenschaften (8)
- Exzellenzcluster Herz-Lungen-System (7)
- Georg-Speyer-Haus (6)
- Pharmazie (6)
- Psychologie (6)
Background: Native T1 may be a sensitive, contrast-free, non-invasive cardiovascular magnetic resonance (CMR) marker of myocardial tissue changes in patients with pulmonary artery hypertension. However, the diagnostic and prognostic value of native T1 mapping in this patient group has not been fully explored. The aim of this work was to determine whether elevation of native T1 in myocardial tissue in pulmonary hypertension: (a) varies according to pulmonary hypertension subtype; (b) has prognostic value and (c) is associated with ventricular function and interaction.
Methods: Data were retrospectively collected from a total of 490 consecutive patients during their clinical 1.5 T CMR assessment at a pulmonary hypertension referral centre in 2015. Three hundred sixty-nine patients had pulmonary hypertension [58 ± 15 years; 66% female], an additional 39 had pulmonary hypertension due to left heart disease [68 ± 13 years; 60% female], 82 patients did not have pulmonary hypertension [55 ± 18; 68% female]. Twenty five healthy subjects were also recruited [58 ±4 years); 51% female]. T1 mapping was performed with a MOdified Look-Locker Inversion Recovery (MOLLI) sequence. T1 prognostic value in patients with pulmonary arterial hypertension was assessed using multivariate Cox proportional hazards regression analysis.
Results: Patients with pulmonary artery hypertension had elevated T1 in the right ventricular (RV) insertion point (pulmonary hypertension patients: T1 = 1060 ± 90 ms; No pulmonary hypertension patients: T1 = 1020 ± 80 ms p < 0.001; healthy subjects T1 = 940 ± 50 ms p < 0.001) with no significant difference between the major pulmonary hypertension subtypes. The RV insertion point was the most successful T1 region for discriminating patients with pulmonary hypertension from healthy subjects (area under the curve = 0.863) however it could not accurately discriminate between patients with and without pulmonary hypertension (area under the curve = 0.654). T1 metrics did not contribute to prediction of overall mortality (septal: p = 0.552; RV insertion point: p = 0.688; left ventricular free wall: p = 0.258). Systolic interventricular septal angle was a significant predictor of T1 in patients with pulmonary hypertension (p < 0.001).
Conclusions: Elevated myocardial native T1 was found to a similar extent in pulmonary hypertension patient subgroups and is independently associated with increased interventricular septal angle. Native T1 mapping may not be of additive value in the diagnostic or prognostic evaluation of patients with pulmonary artery hypertension.
Objective: A high unilateral load to the musculoskeletal system is specific for formation dance. Due to the lack of data the aim of this study was the side-related (right – left) analysis of strength- and balance capability subject to injuries, gender and performance standards.
Methods: N = 51 dancers (m: n = 24, f: m = 27) of two performance levels participated in this cross-sectional study. Double-sided tests of the isometric maximal strength of relevant muscle groups and the balance capability were carried out. The tests were supplemented by a self report questionnaire.
Results: Tests of the isometric maximal strength in the elite performance level showed significant differences between either side of the body. As to the balance capability, no significant side-related differences could be found in. Correlations between the strength capability and the injuries could be observed in either group.
Conclusion: The significant strength differences are presumably caused by the right-sided load in the dance-specific movements. The cautious conclusion that movement patterns challenge the stability of either side of the body likewise may be allowed. The increased injury frequency at the muscularly stronger side of the body primarily results from an overload. An additive muscular training should be considered as a preventive measure.
Blow flies are the first insect group to colonize on a dead body and thus correct species identification is a crucial step in forensic investigations for estimating the minimum postmortem interval, as developmental times are species-specific. Due to the difficulty of traditional morphology-based identification such as the morphological similarity of closely related species and uncovered taxonomic keys for all developmental stages, DNA-based identification has been increasing in interest, especially in high biodiversity areas such as Thailand. In this study, the effectiveness of long mitochondrial cytochrome c oxidase subunit I and II (COI and COII) sequences (1247 and 635 bp, respectively) in identifying 16 species of forensically relevant blow flies in Thailand (Chrysomya bezziana, Chrysomya chani, Chrysomya megacephala, Chrysomya nigripes, Chrysomya pinguis, Chrysomya rufifacies, Chrysomya thanomthini, Chrysomya villeneuvi, Lucilia cuprina, Lucilia papuensis, Lucilia porphyrina, Lucilia sinensis, Hemipyrellia ligurriens, Hemipyrellia pulchra, Hypopygiopsis infumata, and Hypopygiopsis tumrasvini) was assessed using distance-based (Kimura two-parameter distances based on Best Match, Best Close Match, and All Species Barcodes criteria) and tree-based (grouping taxa by sequence similarity in the neighbor-joining tree) methods. Analyses of the obtained sequence data demonstrated that COI and COII genes were effective markers for accurate species identification of the Thai blow flies. This study has not only demonstrated the genetic diversity of Thai blow flies, but also provided a reliable DNA reference database for further use in forensic entomology within the country and other regions where these species exist.
This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH, 85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH → T-DM1 was administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative hormone receptor status, and visceral or brain metastases were associated with more frequent use of this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients. As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of this sequence is similar to that in the approval study.
Biomechanical analysis of the fixation strength of a novel plate for greater tuberosity fractures
(2018)
Background: The incidence of isolated greater tuberosity fractures has been estimated to be 20% of all proximal humeral fractures. It is generally accepted that displaced (>5 mm) fractures should be treated surgically but the optimal surgical fixation of greater tuberosity fractures remains unclear.
Objective: The goal of this study was to simulate the environment of application of a new plate system (Kaisidis plate, Fa Königsee) for fractures of greater tuberosity, and to demonstrate the stability of the plate.
Methods: A Finite Element Method (FEM) simulation analysis was performed on a Kaisidis plate fixed with nine screws, in a greater tuberosity fracture model. Solid Works 2015 simulation software was used for the analysis. The Kaisidis plate is a bone plate intended for greater tuberosity fractures. It is a low profile plate with nine holes for 2,4 mm diameter locking screws, eight suture holes and additional K-wire holes for temporary fixation of the fragment.
The supraspinatus tendon has the greatest effect on the fracture zone, and as such, was the primary focus for this study. For this study, we performed only linear calculations.
Results: The calculations were performed in a way so that the total applied force resulted in a maximum stress of 816 N/mm2. The findings indicated that the most critical points of the Kaisidis system are the screws that are connected to the bone. The maximal force generated by the supraspinatus tendon was 784 N, which is higher than the minimal acceptable force.
The results of the FEM analysis showed that the maximal supraspinatus force was 11.6% higher than the minimal acceptable force. As such, the load would exceed twice the amount of maximal force required to tear the supraspinatus tendon, before the screw or the plate would show first signs of plastic deformation.
Conclusion: Based on the results of this analysis and the fulfilment of our acceptance criterion, the FEM model indicated that the strength of the Kaisidis plate exceeded that of the proposed maximum loads under non-cycli loading conditions.
Uterine fibroids are the most frequent benign tumours in women of child-bearing age. Their symptoms are diverse and the quality of life of the women affected can be significantly impaired. While treatment to date has been primarily by means of surgical intervention, selective progesterone receptor modulators (SPRMs) open up new medication-based treatment options. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has recently completed its review of ESMYA® (ulipristal acetate, 5 mg), following reports of serious liver injury, including liver failure leading to transplantation in postmarketing settings. We will provide some information on the PRAC’s recommendations to minimize this risk. Nevertheless, the effectiveness and safety of the SPRM ulipristal acetate (UPA), both with regard to preoperative administration and with regard to an intermittent administration as long-term treatment for patients with symptomatic uterine fibroids, have been shown in several clinical studies (PEARL I–IV).
In the article titled "Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate", the affiliation of the third author was incorrect. The corrected affiliation is shown above. In addition, the Conflicts of Interest section should be updated as follows ...
The aim of this systematic review and meta-analysis was to compare the peri-implant vertical bone loss of immediate loading of implant crowns using the one abutment at one time (AOT) protocol and implants with abutment removal (AR). This systematic review with meta-analysis was reported according to the PRISMA statement, with guidance from the Cochrane Collaboration Handbook. A total of 103 publications were identified in the PubMed database and reference lists of examined articles. After the screening of titles and abstracts, the eligibility of eight full-text articles was assessed. Five studies published between 2010 and 2015 were included in the meta-analysis. There was less peri-implant vertical bone loss at implants using an AOT protocol than at implants using AR protocol (WMD -0.19, 95% CI -0.26 to -0.13; p<0.0001; random-effects model). In conclusion, the use of the AOT protocol with platform-switched Morse implants results in less bone loss than do AR procedures, but this effect may not be clinically relevant. The preservation of marginal bone level achieved with the AOT protocol may not enhance the aesthetics. These results should be interpreted with caution.
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.
α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis
(2018)
Metastasis formation requires active energy production and is regulated at multiple levels by mitochondrial metabolism. The hyperactive metabolism of cancer cells supports their extreme adaptability and plasticity and facilitates resistance to common anticancer therapies. In spite the potential relevance of a metastasis metabolic control therapy, so far, limited experience is available in this direction. Here, we evaluated the effect of the recently described α-ketoglutarate dehydrogenase (KGDH) inhibitor, (S)-2-[(2,6-dichlorobenzoyl) amino] succinic acid (AA6), in an orthotopic mouse model of breast cancer 4T1 and in other human breast cancer cell lines. In all conditions, AA6 altered Krebs cycle causing intracellular α-ketoglutarate (α-KG) accumulation. Consequently, the activity of the α-KG-dependent epigenetic enzymes, including the DNA demethylation ten-eleven translocation translocation hydroxylases (TETs), was increased. In mice, AA6 injection reduced metastasis formation and increased 5hmC levels in primary tumours. Moreover, in vitro and in vivo treatment with AA6 determined an α-KG accumulation paralleled by an enhanced production of nitric oxide (NO). This epigenetically remodelled metabolic environment efficiently counteracted the initiating steps of tumour invasion inhibiting the epithelial-to-mesenchymal transition (EMT). Mechanistically, AA6 treatment could be linked to upregulation of the NO-sensitive anti-metastatic miRNA 200 family and down-modulation of EMT-associated transcription factor Zeb1 and its CtBP1 cofactor. This scenario led to a decrease of the matrix metalloproteinase 3 (MMP3) and to an impairment of 4T1 aggressiveness. Overall, our data suggest that AA6 determines an α-KG-dependent epigenetic regulation of the TET–miR200–Zeb1/CtBP1–MMP3 axis providing an anti-metastatic effect in a mouse model of breast cancer-associated metastasis.
Background: There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase III JAVELIN Gastric 300 trial compared avelumab versus physician’s choice of chemotherapy as third-line therapy in patients with advanced GC/GEJC.
Patients and methods: Patients with unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited at 147 sites globally. All patients were randomised to receive either avelumab 10 mg/kg by intravenous infusion every 2 weeks or physician’s choice of chemotherapy (paclitaxel 80 mg/m2 on days 1, 8, and 15 or irinotecan 150 mg/m2 on days 1 and 15, each of a 4-week treatment cycle); patients ineligible for chemotherapy received best supportive care. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.
Results: A total of 371 patients were randomised. The trial did not meet its primary end point of improving OS {median, 4.6 versus 5.0 months; hazard ratio (HR)=1.1 [95% confidence interval (CI) 0.9–1.4]; P= 0.81} or the secondary end points of PFS [median, 1.4 versus 2.7 months; HR=1.73 (95% CI 1.4–2.2); P> 0.99] or ORR (2.2% versus 4.3%) in the avelumab versus chemotherapy arms, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 90 patients (48.9%) and 131 patients (74.0%) in the avelumab and chemotherapy arms, respectively. Grade ≥3 TRAEs occurred in 17 patients (9.2%) in the avelumab arm and in 56 patients (31.6%) in the chemotherapy arm.
Conclusions: Treatment of patients with GC/GEJC with single-agent avelumab in the third-line setting did not result in an improvement in OS or PFS compared with chemotherapy. Avelumab showed a more manageable safety profile than chemotherapy.
Trial registration: ClinicalTrials.gov: NCT02625623.
Background: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC).
Patients and methods: ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) and overall survival (OS) were determined in the total cohort and in treatment-related sub-cohorts. Cox regression analyses were carried out to exclude confounders.
Results: Among 216 patients with ALK-rearranged NSCLC, the frequency of pathogenic TP53 mutations was 23.8%, while other co-occurring mutations were rare events. In ALK/TP53 co-mutated patients, median PFS and OS were significantly lower compared with TP53 wildtype patients [PFS 3.9 months (95% CI: 2.4–5.6) versus 10.3 months (95% CI: 8.6–12.0), P < 0.001; OS 15.0 months (95% CI: 5.0–24.9) versus 50.0 months (95% CI: 22.9–77.1), P = 0.002]. This difference was confirmed in all treatment-related subgroups including chemotherapy only [PFS first-line chemotherapy 2.6 months (95% CI: 1.3–4.1) versus 6.2 months (95% CI: 1.8–10.5), P = 0.021; OS 2.0 months (95% CI: 0.0–4.6) versus 9.0 months (95% CI: 6.1–11.9), P = 0.035], crizotinib plus chemotherapy [PFS crizotinib 5.0 months (95% CI: 2.9–7.2) versus 14.0 months (95% CI: 8.0–20.1), P < 0.001; OS 17.0 months (95% CI: 6.7–27.3) versus not reached, P = 0.049] and crizotinib followed by next-generation ALK-inhibitor [PFS next-generation inhibitor 5.4 months (95% CI: 0.1–10.7) versus 9.9 months (95% CI: 6.4–13.5), P = 0.039; OS 7.0 months versus 50.0 months (95% CI: not reached), P = 0.001).
Conclusions: In ALK-rearranged NSCLC co-occurring TP53 mutations predict an unfavorable outcome of systemic therapy. Our observations encourage future research to understand the underlying molecular mechanisms and to improve treatment outcome of the ALK/TP53 co-mutated subgroup.
BACKGROUND: Adjuvant chemotherapy (ACT) for breast cancer improves relapse-free survival (BCRFS) and overall survival. Differences in terms of efficacy and toxicity could partly be explained by the significant interpatient variability in pharmacokinetics which cannot be captured by dosing according to body surface area. Consequently, tailored dosing was prospectively evaluated in the PANTHER trial.
PATIENTS AND METHODS: PANTHER is a multicenter, open-label, randomized phase III trial which compared tailored, dose-dense (DD) epirubicin/cyclophosphamide (E/C) and tailored docetaxel (D) (tDD) with standard interval 5-fluorouracil/E/C and D. The primary end point was BCRFS and the primary efficacy analysis has been previously published. In this secondary analysis, we aimed to retrospectively explore the concept of dose tailoring. Our two hypotheses were that BCRFS would not vary depending on the cumulative administered epirubicin dose; and that dose tailoring would lead to appropriate dosing and improved outcomes for obese patients, who are known to have worse prognosis and increased toxicity after DD ACT.
RESULTS: Patients treated with tDD had similar BCRFS regardless of the cumulative epirubicin dose (P = 0.495), while obese patients in this group [body mass index (BMI) ≥30] had improved BCRFS compared with nonobese ones (BMI <30) [hazard ratio (HR) = 0.51, 95% confidence interval (CI) 0.30-0.89, P = 0.02]. Moreover, tDD was associated with improved BCRFS compared with standard treatment only in obese patients (HR = 0.49, 95% CI 0.26-0.90, P = 0.022) but not in nonobese ones (HR = 0.79, 95% CI 0.60-1.04, P = 0.089). The differences were not formally statistically significant (P for interaction 0.175). There were no differences in terms of toxicity across the epirubicin dose levels or the BMI groups.
CONCLUSIONS: Dose tailoring is a feasible strategy that can potentially improve outcomes in obese patients without increasing toxicity and should be pursued in further clinical studies.
Background: Understanding the location and cell-type specific binding of Transcription Factors (TFs) is important in the study of gene regulation. Computational prediction of TF binding sites is challenging, because TFs often bind only to short DNA motifs and cell-type specific co-factors may work together with the same TF to determine binding. Here, we consider the problem of learning a general model for the prediction of TF binding using DNase1-seq data and TF motif description in form of position specific energy matrices (PSEMs).
Methods: We use TF ChIP-seq data as a gold-standard for model training and evaluation. Our contribution is a novel ensemble learning approach using random forest classifiers. In the context of the ENCODE-DREAM in vivo TF binding site prediction challenge we consider different learning setups.
Results: Our results indicate that the ensemble learning approach is able to better generalize across tissues and cell-types compared to individual tissue-specific classifiers or a classifier applied to the data aggregated across tissues. Furthermore, we show that incorporating DNase1-seq peaks is essential to reduce the false positive rate of TF binding predictions compared to considering the raw DNase1 signal.
Conclusions: Analysis of important features reveals that the models preferentially select motifs of other TFs that are close interaction partners in existing protein protein-interaction networks. Code generated in the scope of this project is available on GitHub: https://github.com/SchulzLab/TFAnalysis (DOI: 10.5281/zenodo.1409697)
A recent randomized study of whipworm Trichuris suis ova (TSO) in ileal Crohn’s disease failed to demonstrate a clinical benefit compared to placebo after 12 weeks. Nonetheless, it has recently been shown that the spontaneous small intestinal inflammatory changes in Nod2-/- (Nucleotide-binding oligomerization domain 2) mice could be substantially ameliorated when these mice were colonized by Trichuris muris. Those and complementary epidemiologic findings in humans lead to the hypothesis that helminths may be advantageous only in patients carrying defective NOD2 variants. Thus, 207 participants of the TSO trial were retrospectively genotyped for six functional NOD2 genetic variants to evaluate whether the treatment outcome differed in patients carrying NOD2 variants. We observed no significant association of the NOD2 variants or their haplotypes with clinical outcome after TSO treatment.
Background: Real‐world evidence is sparse on the benefits of allergen immunotherapy [AIT; subcutaneous/sublingual immunotherapy (SCIT/SLIT)], the only disease‐modifying intervention for allergic rhinitis (AR) with long‐term efficacy. This real‐life study evaluated the effect of six AITs (native pollen SLIT/SCIT, four allergoid SCITs) vs symptomatic medication use, on AR symptoms and asthma symptoms/onset, in patients with birch pollen‐associated AR and/or asthma.
Methods: In this retrospective cohort analysis of a German longitudinal prescription database, AIT patients received ≥2 successive seasonal treatment cycles; non‐AIT patients had ≥3 AR prescriptions in three seasons or previous month. Patients were matched for: index year, age, gender, main indication at index, number of seasonal cycles within treatment period, baseline AR/asthma treatment prescriptions. Multiple regression analysis compared prescription data in AIT and non‐AIT groups as proxy for clinical status/disease progression.
Results: Up to 6 years of follow‐up, significantly more AIT (65.4%) vs non‐AIT (47.4%) patients were AR medication‐free; odds ratio (OR) [95% confidence interval (CI)]: 0.51 [(0.48‐0.54); P < 0.001] (28.6% covariate‐adjusted reduction vs non‐AIT; P < 0.001), and significantly more AIT (49.1%) vs non‐AIT (35.1%) patients were asthma medication‐free [OR (95% CI): 0.59 (0.55‐0.65); P < 0.001] (32% reduction vs non‐AIT; P < 0.001), or reduced existing asthma medication use (32% covariate‐adjusted reduction vs non‐AIT; P < 0.001). During treatment, new‐onset asthma risk was significantly reduced in the AIT vs non‐AIT group (OR: 0.83; P = 0.001).
Conclusions: Birch pollen AIT demonstrated real‐world benefits up to 6 years post‐treatment cessation through significantly reduced AR and asthma medication intake, and significantly decreased risk of new‐onset asthma medication use on‐treatment.
The German Cancer Consortium ('Deutsches Konsortium für Translationale Krebsforschung', DKTK) is a long-term cancer consortium, bringing together the German Cancer Research Center (DKFZ), Germany's largest life science research center, and the leading University Medical Center-based Comprehensive Cancer Centers (CCCs) at seven sites across Germany. DKTK was founded in 2012 following international peer review and has positioned itself since then as the leading network for translational cancer research in Germany. DKTK is long term funded by the German Ministry of Research and Education and the federal states of each DKTK partner site. DKTK acts at the interface between basic and clinical cancer research, one major focus being to generate suitable multisite cooperation structures and provide the basis for including higher numbers of patients and facilitate effective collaborative forward and reverse translational cancer research. The consortium addresses areas of high scientific and medical relevance and develops critical infrastructures, for example, for omics technologies, clinical and research big data exchange and analysis, imaging, and clinical grade drug manufacturing. Moreover, DKTK provides a very attractive environment for interdisciplinary and interinstitutional training and career development for clinician and medical scientists.
Alirocumab reduces total nonfatal cardiovascular and fatal events: The ODYSSEY OUTCOMES trial
(2018)
Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths.
Objectives: This pre-specified analysis determined the extent to which alirocumab reduced total (first and subsequent) nonfatal cardiovascular events and all-cause deaths in ODYSSEY OUTCOMES.
Methods: Hazard functions for total nonfatal cardiovascular events (myocardial infarction, stroke, ischemia-driven coronary revascularization, and hospitalization for unstable angina or heart failure) and death were jointly estimated, linked by a shared frailty accounting for patient risk heterogeneity and correlated within-patient nonfatal events. An association parameter also quantified the strength of the linkage between risk of nonfatal events and death. The model provides accurate relative estimates of nonfatal event risk if nonfatal events are associated with increased risk for death.
Results: With 3,064 first and 5,425 total events, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed with alirocumab compared with placebo. Alirocumab reduced total nonfatal cardiovascular events (hazard ratio: 0.87; 95% confidence interval: 0.82 to 0.93) and death (hazard ratio: 0.83; 95% confidence interval: 0.71 to 0.97) in the presence of a strong association between nonfatal and fatal event risk.
Conclusions: In patients with ACS, the total number of nonfatal cardiovascular events and deaths prevented with alirocumab was twice the number of first events prevented. Consequently, total event reduction is a more comprehensive metric to capture the totality of alirocumab clinical efficacy after ACS.
Aims: Of patients with atrial fibrillation (AF), approximately 10% undergo percutaneous coronary intervention (PCI). We studied the safety and efficacy of dual vs. triple antithrombotic therapy (DAT vs. TAT) in this population.
Methods and results: A systematic review and meta-analysis was conducted using PubMed, Embase, EBSCO, Cochrane database of systematic reviews, Web of Science, and relevant meeting abstracts for Phase 3, randomized trials that compared DAT vs. TAT in patients with AF following PCI. Four trials including 5317 patients were included, of whom 3039 (57%) received DAT. Compared with the TAT arm, Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding showed a reduction by 47% in the DAT arm [4.3% vs. 9.0%; hazard ratio (HR) 0.53, 95% credible interval (CrI) 0.36–0.85, I2 = 42.9%]. In addition, there was no difference in the trial-defined major adverse cardiac events (MACE) (10.4% vs. 10.0%, HR 0.85, 95% CrI 0.48–1.29, I2 = 58.4%), or in individual outcomes of all-cause mortality, cardiac death, myocardial infarction, stent thrombosis, or stroke between the two arms.
Conclusion: Compared with TAT, DAT shows a reduction in TIMI major or minor bleeding by 47% with comparable outcomes of MACE. Our findings support the concept that DAT may be a better option than TAT in many patients with AF following PCI.